2026年生命科学工程与研发洞察报告(英文版)_第1页
2026年生命科学工程与研发洞察报告(英文版)_第2页
2026年生命科学工程与研发洞察报告(英文版)_第3页
2026年生命科学工程与研发洞察报告(英文版)_第4页
2026年生命科学工程与研发洞察报告(英文版)_第5页
已阅读5页,还剩27页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

How

are

life

sciencesengineering

leadersbalancingspeed,agility,and

compliance,in

anageofdisruption?Life

Sciences

EngineeringandR&D

Pulse

Report2026RepoΓt

scopeThisreportpresentsthekeyinsightsfromtheLifeSciences

Engineering

Pulse2026,part

of

ourbroader

cross-sector

Engineering

&

R&D

Pulse.It

is

based

on

a

global

survey

of200senior

lifesciencesleadersfromlargeorganizationsacross

pharmaceuticals,biotechnology,medicaldevices,

anddigitalhealth.Respondentsareseniordecision-makersresponsible

forengineeringacrosstheentireproductlifecycle

–

fromearlyR&Danddesigntoregulatoryandquality

compliance,industrialization,supplychainoperations,andcommercialization.Thequotesandcasestudiesincludedareillustrative

innature,maybedrawnfrompubliclyavailablesources,anddonotnecessarilyreflecttheviewsor

statementsofsurveyrespondents.ReportdemographicsPharmaceuticalsMedTechBiotechnologyLabautomationandresearchtoolsDigital

health

and

Software-as-a-Medical

Device(SaMD)ThedatainthereportwasgatheredbytheCapgeminiResearchInstitutein

August2025via

asurveyofexecutivesatorganizationswithmorethan$1billioninannualrevenue.Thisdataisfromasubsetof200LifeSciencesC-levelandSeniorLeadershipacrossNorth

America,Europe,APAC,andtheMiddleEast.Subsectorbreakdown:Fewindustriessharethelifesciences'weightofresponsibility.EveΓydΓugappΓoved,eveΓydevicedeployed,eveΓytheΓapydevelopedhasadiΓectbeaΓingonhuman

health

and

quality

of

life.Yet

the

oΓganizations

entΓusted

with

thatΓesponsibility

aΓeopeΓating

in

one

of

the

most

complex

enviΓonments

inΓecent

memoΓy

-one

defined

by

geopoliticalvolatility,intensifyingglobalcompetition,acceleΓatingtechnologicaldisΓuption,stΓuctuΓalcostandtime

pΓessuΓes,and

an

unpΓecedented

pace

of

technological

change

dΓiven

by

AI.The

question

this

report

asks

is

a

simple

but

urgent

one:aΓe

life

sciences

oΓganizations

pΓepaΓedto

meet

this

moment?Based

on

the

evidence

gatheΓed

fΓom

senioΓexecutives

acΓoss

the

sectoΓ,

theansweΓisthatwhileambitionishigh,thegapbetweenstΓategicintentandopeΓationalΓeadinessΓemains

significant-and

the

window

to

close

it

is

naΓΓowing.Our

aim

was

threefold:to

undeΓstand

the

foΓces

shaping

the

industΓy’s

stΓategic

agenda;tobenchmaΓk

wheΓe

oΓganizations

cuΓΓently

stand

in

theiΓengineeΓing

tΓansfoΓmation

jouΓneys;andtoidentifythesolutions,models,andtechnologiesthatleadingoΓganizationsaΓedeployingtostay

competitive.In

doing

so,we

sought

not

only

to

suΓface

individual

challenges,but

to

pΓovide

acollective

view-one

that

allows

leadeΓs

to

benchmaΓk

theiΓpΓogΓess,leaΓn

fΓom

peeΓs,and

findshaΓed

solutions

to

shaΓed

pΓoblems.What

you

willlearnA

pΓactical

lens

on

the

foΓcesdΓivingchange

-andthesolutionsleading

oΓganizations

aΓeadopting.KeyfindingsWhatwefoundwasasectorthatis

simultaneouslybrimmingwithopportunityandburdenedbychallengesthatthreatencompetitiveness,resilience,and

innovation.Organizations

are

aligned

on

vision

–

but

not

yet

prepared

to

deliver

at

scale.The

fi∩di∩9s

ofthis

ΓepoΓt

deliveΓ

a

cleaΓ

messa9e:

theco∩veΓ9e∩ce

of9eopolitical

volatility,

acceleΓati∩9

AI

adoptio∩,

deepe∩i∩9

tale∩tshoΓta9es,

a∩dsustai∩ed

cost

a∩d

timeli∩epΓessuΓes

is

fu∩dame∩tally

Γeshapi∩9

life

scie∩ces

e∩9i∩eeΓi∩9.These

foΓces

aΓe

cΓeati∩9

a∩

impoΓta∩t

9ap

betwee∩

stΓate9ic

ambitio∩

a∩d

executio∩

Γeadi∩ess—o∩e

that

the

i∩dustΓy

ca∩

∩o

lo∩9eΓ

a阡oΓd

to

i9∩oΓe.”NirliptaPandaVicePresidentandGlobalHeadofIndustry

LifeSciences|

CapgeminiEngineeringnirlipta.panda@TheurgencyoflifesciencestransformationisrealThepressuresreshapingthelife

sciencessectorGeopoliticaluncertaintyemergesasamajorconcern,with53%oflifesciencesexecutivesnamingitasa

majorthreatand57%acknowledginggapsintheirreadinesstomanageitsimpact.Fromtariffsandtrade

barrierstosovereigntymandatesandglobalconflicts,leadersfaceafragmentedworldwherecross-bordercollaborationisharder.Supplychainfragilityreinforcesthisvulnerability:halfofrespondentssee

disruptions

–including

raw

material

scarcity

–as

a

major

threat,

and47%say

they

are

not

adequatelypreparedforthem.Talentshortages,particularlyincriticaldisciplinessuchasengineering,digital,andAI,areanotherpersistent

pressure

point.Nearly

half,43%,identify

skills

scarcity

as

a

significant

threat,and

almost

asmanyacknowledgetheyareunpreparedtofillthesegaps.Compoundingthisistherapidaccelerationof

AItechnologies,includinggenerativeandagenticAI.Halfof

respondentsseeAIasamajorthreat,butalsoanopportunity,thoughrespondentsarelargelyconfidentin

theirpreparednessforthecomingAIwave,atleastmoresothanotherchallenges.Finally,longstanding

concerns

loom

large.Cost

rises(82%report

increases

over

thelastthree

years)andlengtheninginnovationtimelines(91%saydevelopmentcycleshavelengthened)areseenasproblemsinneedofsolutions.Developmenthorizonscan

be8-10years,3-4of

which

are

dedicated

to

regulatory

processes.90%say

that,to

stay

competitive,they

need

to

reduce

time

spent

on

design

and

development

by5-15%.Thatwillneedtoincludemoreefficiencyincompliance.Allthisisagainstabackdropofrisingglobalcompetition,withforecastsexpecting35%of

FDA

approvals

for

drugs

to

originate

in

China

by2040,up

from

just5%today.[1]Source:

[1]

Morgan

Stanley,“The

Innovation

Boom

in

China

Biotech”,

September2025.Withoutsignificantcostreductions,

ourorganizationrisksbecominguncompetitiveagainststartupsand

emergingmarketplayers

withinthe

nextfive

years.Werisklosingsignificantmarketshare

tostartupsandemergingmarketplayers

withinthenextfive

years,if

wefailtoinnovatefaster.*

Percentageofrespondentsstronglyagreeingwith

thestatementsabove.**lnlightofthesechallenges,whataΓelifesciences

leadeΓs’

stΓategic

pΓioΓities?Compliancefirst

–butagilityistherealdifferentiator.Perhapsunsurprisingly,improvingregulatorycomplianceclearlyleadstheway:65%of

respondentshighlightitsimportance,and45%identifyitastheirtopstrategicconcern.Agilityemergesasthenextkeyareaofattention,with18%sayingitwastheirtoppriority,

and52%sayingitwastheirsecondpriorityaftercompliance.Thatunderscorestheneedfor

faster,moreadaptiveoperations,withmoreflexibletalentpoolsandsupplychains,thatcan

withstandglobalvolatility.Beyondthesetwoareas,companiesrevealedalonglistofstrategicgoalstheyaspiredto.Cost

savings(48%)and

reducing

time

to

market(45%)were

both

high

on

the

agenda.Relatedtothese,48%saidthatembracingdigitaltechnologiestoinnovatewasanimportant

priority.Asaresult,lifesciencesleadersfaceachallengingtime.Tostaycompetitive,theymust

becomemoreagiletothriveinavolatileworld.Theymustalsoreducecostsandshorten

innovationcycles,whileadheringtoregulatory&complianceguidelines

–allwithoutcompromisingsafety.Howcantheydoallofthistogether?Sources:[2]

Takeda

–Press

release,“Changes

to

Fuel

Speed,Competitiveness

and

Future

Growth”,January2026.[3]

Pfizer

–CEO

Letter,Annual

Review2025.Thechangesannouncedtodayarethecatalyst

for

our

nextera,enablingsimplicity,speed

and

efficiency

–without

sacrificingquality

–tohelpus

moveat

pacetobringlife-transformingmedicinestopatients.

”Julie

Kim|CEO-Elect,Takeda[2]We’re

striving

to

increase

the

speed

ofeverythingwedotodrivehigh-quality

innovationtoimprovelives.

”DΓ.AlbeΓtBouΓlaIChairman&CEO,Pfizer[3]How

are

life

sciences

leadersresponding

to

these

challenges?Turningpressure

intoactionHowarelifesciencesleaders

attemptingtobuildagile,resilient

organizations,whichcutcostsandcompressinnovationcycles,all

whileensuringcomplianceisstrictlyadheredto?Threedominantareasemergefromthefindings:Shiftingtoglobal

operatingmodelsand

accessingglobaltalentRead

more>Read

more>Read

more>Increasingorganizational

agilityEmbracingAI

and

newtechnologiesHighlights84%areinvestingindigitaltoolstobetter

anticipateshocks79%areimplementingflexibleoperational

systemstodynamicallyscaleproduction71%citelimitedsupplychainflexibility67%struggletoreallocateresourcesIncreasingorganizationalagilityAsmarketconditionsbecomemoreunpredictable

–shapedbygeopoliticalshifts,fluctuatingdemand,andsupplychainfragility

–lifesciencescompaniesareprioritizingagilityitselfasacorestrategiccapability.Manyareacceleratingeffortstobuildmoreflexibleoperating

modelsthatcanrespondquicklyandefficientlytochangingneeds.Agilityisnot

justaboutrespondingtobigchangeslikeawarorapandemic.Itisalsoaboutconstantlyadjustingtheorganizationtoenable

rapid,cost-effectiveinnovation,suchasquicklyscalingupsoftwarecapabilities,orbeingabletodeploynewproductivity-boosting

innovations,likeAIorrobotics,intoexistingprocesses.Nearlyeightintenorganizations(79%)areimplementingflexibleoperationalsystems,includingmodularproductionlines,adaptivestaffing

approaches,andreal-timescheduling,todynamicallyscalecapacityupor

down

in

line

with

demand(Chart3).Such

approaches

also

make

it

easier

totransferorscalecapabilitybetweenfacilitieswhenneedschange.Atthesametime,85%areinvestingindigitaltoolsforscenarioplanning

toanticipateexternalshocks,liketariffsorregulatorychanges,andtomodelimpactsandresponseswithgreaterprecision.We

see

several

examples

of

this,for

example

Joaquin

Duato,Chairman&

CEOof

Johnson&Johnson,hasmadedigitaltransformationacentralplankofhisleadership,deployingpredictiveanalyticsthathavetrimmed

inventorywrite-offsbyanestimated$400million.IncreasingorganizationalagilityAgility

inaction:ManufacturingupgradesatscaleSanofi’sMARS(MES

Accelerated

Roadmap@Sanofi)programis

delivered

incollaboration

withpartners,includingCapgemini[4].MARS

is

a

large-scale

digital

manufacturing

initiative

to

standardizethecompany’sManufacturingExecutionSystem

(MES)globallyandreplace

paper-based

batch

records

with

electronic

ones.Usingastandardized

MESmodelandadvancedtechnologies–including

generative

AItohelpconvert

recipesandworkflowsintodigital

MESconfigurations

–the

programhasdelivered

significantgains.

Thoseincludea

70%reductioninbatchreviewtimeandan80%decreaseinproductiondeviations.MARShasbeendeployedat25manufacturing

sites

and

used

by

more

than4,000

people,

with

aroadmap

targeting52sites

by2027.However,achievingtrueagilityremains

challenging.Two-thirdsofexecutives(67%)reportdifficultyreallocatingresources

–whetherpeople,capital,orassets

–acrossprojectsorgeographicregions,

limitingtheirabilitytopivotinrealtime.Supplychainrigidityisalsoamajorbarrier,with71%citinginsufficientvisibilityorflexibilityacrosssourcinganddistributionnetworks.Internally,organizationalresistanceto

changepersists,with61%ofleadersnotingculturalorstructuralpushbackthatslowsorcomplicatestransformationinitiatives.Anagileorganizationrequires

joined-updigitalsystemsacrosssilosand

supplychains,data-drivenintelligence,standardization,modularinfrastructureandacollaborativeculture.Whileagilityisastrategicobjectiveinitsownright,withitsowninternalinvestmentdemands,its

successwillalsodependondigitaltechnologiesandflexibleglobaloperatingmodels

–whicharethesubjectofthefollowingsections.Source:[4]

Siemens

–Corporate

blog,“Driving

Pharma

Manufacturing

Excellence:Sanofi,Capgemini

and

Siemenson

Scaling

MES

with

Generative

AI”,September2025.IncreasingorganizationalagilityAgility

inaction:Real-timemonitoringforagileoperationsA9lobalbiotech&dia9∩osticsleadeΓ,

woΓki∩9with

Cap9emi∩ia∩dotheΓ

paΓt∩eΓs,istΓa∩sfoΓmi∩9ma∩ufactuΓi∩9opeΓatio∩sthΓou9h

a

cloud-based

i∩dustΓialdataplatfoΓm,

whiche∩ables

seamlessi∩te9Γatio∩of

opeΓatio∩ala∩de∩teΓpΓisedataacΓoss

9lobal

sites.

ThepΓojectΓeplaces

fΓa9me∩teddatasiloswithasi∩9le,co∩textualized

souΓceoftΓuth.

ThisdΓamaticallyΓeducesi∩fΓastΓuctuΓecomplexitya∩ddatavolumes,

whileimpΓovi∩9accessibility

foΓ

busi∩essa∩d

e∩9i∩eeΓi∩9teams.Withi∩

lesstha∩

thΓeemo∩ths,

thepΓojecte∩abled

self-seΓvicea∩alytics,

a∩ddi9italmai∩te∩a∩cea∩dpΓedictivemo∩itoΓi∩9usecases

ofcΓiticalassets,

likece∩tΓifu9esa∩d

bioΓeactoΓs.

ThesecapabilitiessuppoΓtfasteΓ

i∩si9hts,impΓovedequipme∩tΓeliability,a∩d

scalable

a∩alyticsdeployme∩t.Highlights74%will

increase

AI

investment

by10%ormoreinthecoming

years72%areconcernedaroundAIreliabilityand

accuracy68%see

AI

benefits

across

the

R&D

lifecycle,

fromconceptdesigntocomplianceto

manufacturing60%EmbracingAIandnewtechnologiesLifesciencesorganizationsareincreasinglyembracingAIalongsideabroadersetofdigitaltechnologiestoaddressspeed,cost,andcomplexity

across

engineering

and

R&D.Thesetechnologiesareseenaspracticalenablerstoimproveproductivity,

strengthencompliance,andincreaseoperationalresilience.Whileadoptionisprogressing,thechallengeliesinscalingandintegrating

thesesolutionseffectivelywithincomplex,highlyregulatedenvironments.Successincreasinglydependsoncombiningtechnologicalinnovationwith

robustgovernance,clearoperatingmodels,andstrongchangemanagement.OrganizationsthatcanmovebeyondpilotstoembedAIand

digitalcapabilitiesend-to-endarebetterpositionedtotranslateambition

intomeasurableimpact.seeAIashighlytransformativeEmbracingAIandnewtechnologiesAIisoneofthebiggestdisruptivethreatsand

biggestopportunities.AI

was

seen

as

having

high

transformative

potential

by60%ofrespondents.Halftotwo-thirdsseeitastransformativeinareasfromresearchtomaintenancesupport(seeA/

inactionattheendof

this

section).58%saw

it

as

having

high

potential

to

address

one

oftheirtopstrategicpriorities:reducingthetimerequiredforcompliance.Indeed,manyexecutivesarealreadyseeingbenefitsfromAIindeliveringstrategicpriorities,withsignificant

AI-relatedimprovementsinproductivity,costreduction,andtimetomarket

(Chart4).Andtherearehighexpectationsofmuchgreaterbenefitsin

the

near

future(Chart5).Life

sciences

leaders

are

optimistic

about

AI.In

fact,94%believe

they

areahead

of

their

peers.This

suggests

that,in

most

companies,there

is

asensethattheyareadvancingwellwithAI,eveniftheydonotrealizethat

theircompetitorsaredoingthesame.Organizationsarealsoquitematureintheiruseof

AI,atleastthetraditional

sort.Most(86%)are

at

the

deployment

stage

–with

live

AI

inlimitedareas,butnotfullyintegratedacrossthebusiness.ForgenerativeAI(GenAI),most(82%)are

in

the

piloting

stage,and

for

agentic

AI,84%

arestillexploringitspotential.Makinghuman-machinecollaborationmorewidelyavailable

allows

engineers

to

accelerate

code

development,increaseinnovationandtackle

skilled

labour

shortages.

”Roland

Busch

|

CEO,

Siemens

AG

[5]Source:[5]

Siemens

–Press

release,“Siemens

and

Microsoft

partner

to

drive

cross-industry

AI

adoption”,October2023.EmbΓacin9Alandnewtechnolo9iesAIinvestmentsettosurge,butchallengesareonthehorizon.Ambitions

are

high.47%say

their

organization

has

allocated

5-20%of

its

total

engineering

and

R&D

budget

to

AI-relatedinitiatives,and

over90%say

that

budget

will

increase

by5-20%over

the

next2-3years(Chart6).But

AI–especially

GenAI–comes

with

challenges.RespondentscitedconcernsaboutAI,rangingfromworries

around

reliability

and

accuracy

of

outputs(72%saying

amajorconcern)tothehighenvironmentalfootprintofGenAIand

agentic

AI(67%),to

their

own

lack

of

internalgovernance

frameworks

for

GenAI

and

agentic

AI(68%).This

is

slowing

adoption(Chart7).Theseareallgenuineconcernstonavigate,butperhapsthe

biggestthreattolifesciencescompaniesisnotembracingAI

andfindingthatitdoesliveuptoitspromise...fortheircompetitors.EmbracingAIandnewtechnologiesActivityResearch&conceptdevelopmentDesign&prototypingSimulation&testingDocumentation,compliance&IPmanagementManufacturing&operationsMaintenance&supportPercentsaying

AIwill

transformin2-3

years49%45%38%58%48%68%AI

opportunities

AI-powered

literatureanalysis,ideagenerationGenerativedesign,

AI-assistedCAD,rapidprototyping,designoptimizationAI-enhancedsimulation,

anomalydetectionAI-generateddocumentation,automatedcompliance

checks,patentlandscape

analysisAI-basedproductionscheduling,computer

vision

forqualitycontrol,predictivesupplychainplanning,autonomousmaterialhandlingAI-baseddiagnostics,predictivemaintenance

planning,intelligentsupportbotsCase

studies

Pfizer

is

using

GenAI

to–often

up

to20,000documentsperdrug.By

enablingnaturallanguage

andvoice-basedqueriesacrossmultiplerepositories,

AIsignificantlyreduces

manualeffort.Thispotentiallysavesupto16,000hoursandcanaccelerateearly-stageresearch.[6]Medtronicisexploringthe

useofgenerative

AItosupportengineersinmedicaldeviceresearchanddevelopment.Thesetechnologieshelpteamsgenerateandevaluatedesignconcepts,accelerate

early-stageengineeringwork,andimproveproductivitybyassisting

–

ratherthanreplacing

–engineeringexpertise.[7]Roche

is

applyingAI-drivenmodelstosupportdrugdiscoveryanddevelopmentbyimprovingmolecularunderstandingandsupportingdata-drivenscientificdecision-making.

Theseapproacheshelpresearchersprioritizetargetsandexplorecomplexbiologicalinteractionsmoreeffectively.[8]A

German

MedTechcompanypartneredwith

Capgeminitoautomatetheextractionofregulatoryrequirements

using

GenAI.Using

largelanguagemodelsandcomputervision,thesolutioninterpretstext,

tables,andimagesfrom

regulatorydocuments,andstandardizesoutputs.Thetoolreducedmanual

effortanderrors,achieving60%resourceoptimizationwhilealsoimprovingcomplianceaccuracy.It

was

designedforscalabilityandhasnow

beenadaptedtoavariety

ofregulatoryentitiesand

cases.Sanofi,Capgemini,andindustryandacademicpartnersareadvancingbiologicsmanufacturingthroughCALIPSO,a€17.5millioninitiativetomodernizebioproduction.Using

advanced

sensors,data

platforms,anddigitaltwins,

theprojectimprovesprocess

monitoring,prediction,and

control.Thiscouldpotentiallyincreaseproductivitytenfold,

while

acceleratingbiologicsdevelopmentandimproving

batchquality.[9]Apharmaceuticalcompanypartneredwith

Capgeminiandsoftware

providerstoimplement

anindustrialDataOpsplatformacrossitssites.

Thisunifyingofdatafor

intelligentassetlifecycle

managementhasincreasedcapacityutilization

by10%,extendedassetlifetimesby20%,and

reducedhuman-errorrisksbyupto80%.Johnson&Johnson

isusingadvancedanalyticsand

AI-enabledplanning

toolstostrengthensupply-chainresilience.Openfulltable

in

browser:

https://capgemini.turtl.co/story/lifesciences-erandd-pulse2026/page/3/10

networks

AIacrosstheLifeScienceslifecyclehelpscientistssearchandextractinsightsfromvast

volumesofresearchdatasupply

chain

technology

is

helping

transform

how

we

work

and

live”,2024.mining,feasibilityBeyond

AI:thewiderdigitalinnovationlandscapeLeadersareexploringabroadsetoftechnologies

–butscalingremainsuneven.Theexcitementof

AIshouldnotobscurethevalueofothertechnologies,andindeedrespondentsshowedappetitefora

widerangeoftechnologieswithpotentialtoimproveefficiency,

innovation,cost,andcompliance

(Chart8).EmbracingAIandnewtechnologiesInnovationinaction:QuantumcomputingfordrugdiscoveryQuantumcomputingisbeingexplored

asa

futurecomplementtoclassical

high-performance

computing

in

early-stage

drug

discovery.

Its

primary

potentialliesinmolecular

simulationand

quantumchemistry,

where

quantum

methods

could,in

the

long

term,modelelectronic

structuresand

reactionmechanismswithhigher

accuracythan

classical

approaches.In

the

near

to

mid-term,most

applicationsrelyonhybrid

quantum–classicalapproaches,combiningclassicalsimulations,AI/ML

models,and

quantum-derived

features.

Theseapproachesaimtoimprovethequalityof

molecular

predictionsand

candidate

prioritization,ratherthanreplaceexistingcomputational

chemistryand

laboratoryworkflows.Whileoptimismfortechnologywaspositive,someresultsraise

potential

concerns.80%of

respondents

said

they

wereexploringimmersivetechnologies,

yetthishasbeenthecase

for

years.Thissuggestseithertheyarenotdeliveringashoped

–at

least

not

at

scale

–or

something

is

blockingprogress.Digitaltwinscouldbeasimilarstory.Inengineering,digital

twinshavealreadydeliveredsometransformativeoutcomes,

yet

in

life

sciences,75%are

still

only

at

the

piloting

stage,and

just9%at

the

deployment

stage.This

is

low

consideringthetechnologyhasprovenusecases,butnotoutoflinewith

otherindustries.When

it

comes

to

deploying

digital

technologies,AI

–

at86%

deployment

–seemstobesignificantlyaheadofthegame.Newertechnologies,includinghumanoidrobotsandquantum,were

on

the

agenda,with76and77%respectivelyexploringthese.It’stooearlyto

judgeprogressoneither,but

reassuringtoseefrontiertechnologieslikethesebeingtaken

seriously.Shiftingtoglobaloperatingmodels

andaccessingglobaltalentGlobaloperatingmodelsholdpromiseforallthreepriorities:increasedagility,faster

innovation,andcostreduction.Accessingglobaltalentpoolscanbakeinagilityandresilience,removingbottlenecksthatslowinnovationandproductioncausedbytalent

scarcityintraditionaloperatinglocations.Thistransformationisnotnew,butthedata

impliesachangeinapproach

–fromacost-cuttingexercisetoastrategicleverthatenablesflexibilityandtimescalereduction.Overhalfofcompanies(57%)alreadyoperatestrategicallyfocusedoffshore/remote

Centers

of

Excellence

and77%plan

to

increase

their

use.Such

Centers

of

Excellence

giveorganizationsacentralizedhubofspecializedexpertise

–withstandardizedbest

practices,optimizedprocessesandcutting-edgetechnologies

–thatsupporthigh-quality,high-productivitydeliveryatscale.76%already

right

shore

and

co-source

specific

engineering&operations

activities

–and62%plan

to

increase

this

approach

for

defined

work

packages

over

the

comingyears.Highlights83%intendtoincreaseperformance-based

outsourcing77%plantoexpandoffshoreCentersofExcellence

–ashifttowardmorestrategic

globalmodels76%already

outsource

engineering

or

R&D

activitiesOthersignsofamovetowardsmorestrategicglobaloperatingmodelsemergefromthedata.Forexample,

83%plan

to

increase

performance-based

outsourcing,

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论